PRISM Stock IndexesCurrent Value% Change (Daily)% Change (Inception)Most ActiveTop % GainersTop % Losers
AdTech and Media$81.60-2.3%-18.4%SIRI 23,513 SIRI  4.528%BBLR -13.5%
Biotech$181.90-2.2%81.9%IBIO 3,888 VXRT  30.16%SLS -15.2%
Cannabis$112.100.3%12.1%TLRY 33,674 MAPS  5.825%CARA -4.713%
Consumer Products$84.40-2.1%-15.6%PTON 16,473 BOF  1.333%NUZE -5.488%
EV$71.00-3.8%-29.0%NKLA 88,475 GP  0.909%PSNY -18.104%
Global Health$81.50-4.3%-18.5%LGVN 8,360 GOSS  4.288%AVTE -14.546%
Healthcare$80.20-3.9%-19.8%HIMS 9,113 NOTV  2.941%CCLD -18.884%
NextGen Tech & AI$82.60-0.8%-17.4%SOUN 30,508 SKYX  13.274%BNAI -13.075%
New Energy$80.701.4%-19.3%DNN 16,139 NOVA  8.515%MAXN -3.478%
MedDevices$90.50-1.6%-9.5%AEMD 4,177 SSII  14%CTSO -9.506%
Mental Health$60.00-3.1%-40.0%VNDA 2,585 AVXL  4.022%CING -14.925%
Oil & Gas$91.00-0.2%-9.0%SWN 12,965 TALO  5.299%BATL -8.686%
Pharmaceuticals$88.80-2%-11.2%CADL 5,757 TNXP  8.929%KALA -10.035%
Psychedelics$92.00-0%-8.0%CYBN 4,072 CMND  11.818%CMPS -5.441%
Women’s Health$92.70-3.7%-7.3%PDSB 777 PTN  13.736%LPCN -32.834%
Zombie$97.20-0.1%-2.8%AMC 58,691 CHWY  13.854%RNG -3.926%

Prism View

Europe Goes Solar Eh? Canadian Solar (CSIQ) To Present EP Cube for Residential Energy Storage at Intersolar in Munich

Canadian Solar Inc. (CSIQ) today announced that it will unveil its new three-phase EP Cube and EP Cube Twin Peak at Intersolar in Munich, Germany, from June 19-21, 2024. This expansion of the EP Cube residential energy storage line aims…

“Houston, We Have Oil.” Houston American (HUSA) Announces Drilling Plans in Texas

PRISM Oil and Gas Index company, Houston American Energy Corp. (HUSA) has announced plans to participate in the drilling of six wells on the State Finkle Unit in the Wolfcamp formation in Reeves County, TX. The primary operator of this…

Stocks making the biggest moves premarket: La-Z-Boy, NextEra Energy, Kroger, Lennar and more

Here is a look into companies making waves in premarket trading. La-Z-Boy shares saw a significant surge of over 9% following a better than expected quarterly report. The furniture company's fiscal fourth quarter adjusted earnings came in at 95 cents…

EV Maker Polestar (PSNY) is Working to Put Itself in Pole Position with Expansion News

The EV maker Polestar Automotive (PSNY) announced its plans to expand its commercial footprint and retail…

Magnite (MGNI) Prepares for Take Off and Partners with United (UAL) to Provide Advertising Solution for Inflight Personal Entertainment

PRISM AdTech and Media Index company, Magnite (MGNI) who is also the largest independent sell-side advertising…

Stocks making the biggest moves premarket: Best Buy, Toll Brothers, Autodesk and more

Toll Brothers — This homebuilder saw a 1.3% rise, thanks to an upgrade to neutral from…

Stocks making the biggest moves midday: Adobe, RH, Hasbro and more

Here's an update on some notable movements in the market during midday trading: Adobe made headlines…

Stocks making the biggest moves premarket: Adobe, Hasbro, GameStop and more

Here's the scoop on the companies that had people talking before the stock market opened. GameStop…

Roaring Kitty Pounces on More GameStop Shares in Latest Meme Stock Frenzy

Keith Gill, better known as "Roaring Kitty," a key figure in the meme stock phenomenon, has…

Feature Story

The GLP-1 Gold Rush Continues

A 2024 report from GlobalData has revealed that in spite of approaching headwinds in the obesity market, glucagon-like peptide-1 (GLP-1) receptor agonists will continue to generate blockbuster sales. The analysis projected that sales will reach a total value of $111 billion by 2033 after achieving $25 billion in 2023 in the US, France, Spain, Germany, Italy, Japan, and the UK.

Obesity is a rising public health concern that affects 42% of adults in the US, and over one billion people worldwide. It is associated with an increased risk of overall mortality and serious health conditions, including high blood pressure, high cholesterol, type 2 diabetes, heart disease, stroke and cancer. Safe and effective obesity treatments remain a critical unmet need.


Q&A Corner

Jason Matuszewski, CEO Biostem Technologies
Jason Matuszewski

BioStem Technologies: Soaring Revenues, Robust Growth and Expansion into New Markets

After a highly successful start to 2024, BioStem Technologies (OTC: BSEM) is on track to achieve multiple milestones during the year. The biotechnology company is consolidating its debt, pursuing a potential uplisting to a senior stock exchange, and initiating a clinical trial to showcase the effectiveness of its products in a real-world clinical setting.

The company has experienced a surge in growth over the past 12 months, reporting revenues of $41.9 million in the first quarter of the year, a significant increase over the $600,000 reported in the same period last year. BioStem is on track to meet multiple milestones and deliver long term value for investors.

PRISM MarketView spoke with BioStem’s CEO, Jason Matuszewski about the next phase of the company’s journey, which is expected to bring robust growth and a clear path to expanding into new markets.

Traders Lens

Intra-Cellular Therapies Inc.

$ITCI is leading the Prism MarketView Psychedelics index today after the company said a Phase 3 trial of its depression treatment met its primary and secondary endpoints. The trial drug lumateperone, is being developed for use in the treatment of major depressive disorders.

Longeveron Inc.

Shares of biotech company $LGVN continue to surge today after yesterdays big move, when the company released Phase 2 trial data of Lomocel-B, a treatment for patients suffering from hypoplastic left heart syndrome.

Avidity Biosciences Inc.

RNA therapeutics company $RNA is reaching all-time highs today after posting initial data from its FORTITUDE trial for its experimental therapy del-brax (AOC 1020) in the treatment of a rare muscular disorder.

Bio View

Aerovate Therapeutics Misses Primary Endpoint in Hypertension Trial, Shares Drop 93%

Shares in Aerovate Therapeutics (Nasdaq: AVTE) fell by almost 100% on Monday after the company announced topline results from its Phase 2b, trial of AV-101, a novel dry powder inhaled formulation of imatinib, in adults with pulmonary arterial hypertension (PAH).…

Tiziana Life Sciences Aims to Fast-Track Multiple Sclerosis Treatment with FDA Submission

Tiziana Life Sciences (Nasdaq: TLSA) has received acceptance from the FDA  of its submission for intranasal foralumab to receive Fast Track Designation approval for the treatment of non-active, secondary-progressive multiple sclerosis (na-SPMS). The company is developing intranasal foralumab for the…

Quoin Pharmaceuticals Cements Leadership Position in Rare Diseases with New Research Agreement

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a specialty pharmaceutical company focused on rare and orphan diseases, announced a research agreement with The School of Pharmacy at University College Cork (UCC) in Ireland. This collaboration, aimed at developing innovative topical formulations of…

Cardiol Therapeutics’ CardiolRx™ Demonstrates Marked Reduction in Pericarditis Pain

Clinical-stage life sciences company, Cardiol Therapeutics (Nasdaq: CRDL) has demonstrated a marked reduction in pericarditis pain…

Longeveron Completes Investigator Meeting in Pediatric Heart Trial, Shares Rise

Regenerative medicine company, Longeveron (Nasdaq: LGVN) topped the PRISM MarketView Global Health index on Wednesday after…

SS Innovations Secures Regulatory Approval in Indonesia for Flagship Surgical Robotic System

Leading developer of innovative surgical robotic technologies, SS Innovations International (OTC: SSII) has secured regulatory approval…

Capricor Therapeutics Advances Treatment for Duchenne Muscular Dystrophy

Shares in biotechnology company Capricor Therapeutics (Nasdaq: CAPR), rose on Tuesday after the company announced that…
PRISM Indexes

Dell and Nvidia collaborate to power Musk’s Grok AI factory

Grok, a generative AI chatbot, was created as a response to the increasing popularity of ChatGPT, a product of OpenAI, which Musk co-founded. Grok, which… [Read More]